Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Juvenile Macular Degeneration (Stargardt Disease)-Pipeline Review, H1 2015

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Juvenile Macular Degeneration (Stargardt Disease)-Pipeline Review, H1 2015', provides an overview of the Juvenile Macular Degeneration (Stargardt Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Juvenile Macular Degeneration (Stargardt Disease) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Juvenile Macular Degeneration (Stargardt Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Juvenile Macular Degeneration (Stargardt Disease) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Juvenile Macular Degeneration (Stargardt Disease) Overview 6

Therapeutics Development 7

Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease)-Overview 7

Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease)-Comparative Analysis 8

Juvenile Macular Degeneration (Stargardt Disease)-Therapeutics under Development by Companies 9

Juvenile Macular Degeneration (Stargardt Disease)-Therapeutics under Investigation by Universities/Institutes 10

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Juvenile Macular Degeneration (Stargardt Disease)-Products under Development by Companies 13

Juvenile Macular Degeneration (Stargardt Disease)-Products under Investigation by Universities/Institutes 14

Juvenile Macular Degeneration (Stargardt Disease)-Companies Involved in Therapeutics Development 15

Acucela Inc. 15

Alkeus Pharmaceuticals, Inc. 16

Ocata Therapeutics, Inc. 17

Sanofi 18

Juvenile Macular Degeneration (Stargardt Disease)-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

ALK-001-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

echothiophate iodide-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

emixustat hydrochloride-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Gene Therapy for Stargardt Disease-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

MA09-hRPE-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule for Stargardt Disease-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

StarGen-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

VSM-20R-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Juvenile Macular Degeneration (Stargardt Disease)-Recent Pipeline Updates 40

Juvenile Macular Degeneration (Stargardt Disease)-Product Development Milestones 51

Featured News & Press Releases 51

Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration 51

Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom 52

Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 52

May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 53

Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration 53

Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt's Macular Dystrophy 54

Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 54

Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells 55

Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone 56

Dec 17, 2012: ACT Completes Higher-Dosage Cohort In European Clinical Trial For Stargardt's Macular Dystrophy Using Retinal Pigment Epithelial Cells 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 59

Disclaimer 59

List of Tables

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2015 7

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease)-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Products under Investigation by Universities/Institutes, H1 2015 14

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline by Acucela Inc., H1 2015 15

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline by Alkeus Pharmaceuticals, Inc., H1 2015 16

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline by Ocata Therapeutics, Inc., H1 2015 17

Juvenile Macular Degeneration (Stargardt Disease)-Pipeline by Sanofi, H1 2015 18

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Stage and Target, H1 2015 21

Number of Products by Stage and Mechanism of Action, H1 2015 23

Number of Products by Stage and Route of Administration, H1 2015 25

Number of Products by Stage and Molecule Type, H1 2015 27

Juvenile Macular Degeneration (Stargardt Disease) Therapeutics-Recent Pipeline Updates, H1 2015 40

List of Figures

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2015 7

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease)-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Top 10 Targets, H1 2015 20

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 26

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acucela Inc.

Alkeus Pharmaceuticals, Inc.

Ocata Therapeutics, Inc.

Sanofi

Juvenile Macular Degeneration (Stargardt Disease) Therapeutic Products under Development, Key Players in Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Juvenile Macular Degeneration (Stargardt Disease) Pipeline Overview, Juvenile Macular Degeneration (Stargardt Disease) Pipeline, Juvenile Macular Degeneration (Stargardt Disease) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com